3.57

5.31% -0.20

After Hours: 3.57

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $3.57, with a volume of 878.41K. It is down -5.31% in the last 24 hours and down -58.25% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Previous Close:

$3.77

Open:

$3.75

24h Volume:

878.41K

Relative Volume:

0.49

Market Cap:

$225.89M

Revenue:

$2.81M

Net Income/Loss:

$-97.34M

P/E Ratio:

-1.9833

EPS:

-1.8

Net Cash Flow:

$-91.47M

1W Performance:

+11.56%

1M Performance:

-58.25%

6M Performance:

-62.18%

1Y Performance:

-19.59%

1-Day Range:

$3.57

$3.83

1-Week Range:

$3.10

$4.75

52-Week Range:

$2.865

$13.70

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2024-07-31

Latest SEC Filings

FULC's Discussions on Twitter

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

08:40 AM

Are Fulcrum Therapeutics Inc (FULC) shares a good deal now? - US Post News

08:40 AM

07:51 AM

FULC Stock on the Rise: A Promising Investment - The InvestChronicle

07:51 AM

Sep 29, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Growth in Short Interest - MarketBeat

Sep 29, 2024

Sep 27, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - AccessWire

Sep 27, 2024

Sep 26, 2024

Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback - MSN

Sep 26, 2024

Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback - Seeking Alpha

Sep 26, 2024

Fulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market Opportunity - MarketWatch

Sep 26, 2024

The Significance of Moving Averages in Fulcrum Therapeutics Inc Inc. (FULC) Price Performance - The InvestChronicle

Sep 26, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation - AccessWire

Sep 26, 2024

Sep 25, 2024

Fulcrum Therapeutics to cut jobs after dystrophy drug failure - The Business Journals

Sep 25, 2024

Sep 24, 2024

Fulcrum Therapeutics to Cut 29 Jobs Amid Reprioritization of R&D - MarketWatch

Sep 24, 2024

Fulcrum Therapeutics announces workforce reduction - Investing.com

Sep 24, 2024

Fulcrum Therapeutics announces workforce reduction By Investing.com - Investing.com UK

Sep 24, 2024